AbbVie Inc. with ticker code (ABBV) now have 29 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $240.00 and $165.00 and has a mean share price target at $204.74. (at the time of writing). Given that the stocks previous close was at $171.73 and the analysts are correct then there would likely be a percentage uptick in value of 19.2%. There is a 50 day moving average of $189.45 and the 200 day MA is $178.87. The company has a market cap of 312.70B. The stock price is currently at: $176.95 USD
The potential market cap would be $372,793,050,610 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 61.66, revenue per share of $31.40 and a 7.72% return on assets.
AbbVie Inc. (AbbVie) is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in various therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica and Venclexta/Venclyxto; aesthetics products that include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; eye care products, which consists of Lumigan/Ganfort, Alphagan/Combigan and Restasis, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from the AbbVie-owned distribution centers and public warehouses.
